Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustment

Narasimhan
“We're watching very closely the whole development of this policy,” Narasimhan told Fierce in regards to the implementation of the COINS Act. (Fabrice Coffrini/AFP/Getty Images)

Despite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.

Tensions came to a head in September, when reports surfaced that certain investors wanted a change in M&A strategy. Those reactions were triggered by del-desiran—the centerpiece of a $12 billion acquisition of Avidity Biosciences—failing in a rare muscle-wasting disease soon after a phase 3 failure for the Lp(a) candidate pelacarsen suffered its own phase 3 defeat in a cardiovascular disease. 

Those high-profile fails initially wiped out around 10% of the Swiss pharma’s share price—erasing nearly $30 billion from its market cap—although the stock has since recovered most of that ground.

On a call with journalists on Thursday morning to kick off a Meet Novartis Management event, Fierce asked Narasimhan if he felt under any pressure from investors to change the company’s approach.

“I think when we take a 10-year view, see that our overall total shareholder return has been well north of 200%, and actually one of the top consistently above peer median and top five in the sector,” the CEO responded.

“So I think overall shareholders are happy with our approach,” Narasimhan continued. “Obviously, there's always going to be different perspectives on how to approach M&A, and I think that's normal. Some shareholders were very pro-high-growth M&A; other shareholders would prefer a different capital allocation strategy.” 

“But I think … the capital allocation strategy that we've had has been extremely successful now over a 10-year period,” he added. “I mean, when you look at it, a 10-year shareholder return of 275% with the allocation that we've had—I think that speaks for itself.”

Across the management day, Narasimhan and his fellow executives aimed to update investors on the company’s strategy, which includes over 35 “potentially submission-enabling readouts through 2031,” the CEO explained.

Novartis’ C-suite are keen to point to 30 potential high-value assets across four priority therapeutic areas. They include: abelacimab, a factor XI/XIa inhibitor for stroke prevention in atrial fibrillation; ianalumab, a IgG1 monoclonal antibody for systemic lupus erythematosus; del-brax, an RNA therapeutic for facioscapulohumeral muscular dystrophy; and pelabresib, a BET inhibitor in myelofibrosis.

The company narrowed its growth expectations for 2026-2031 from 5-6% to 5%, which Narasimhan explained on the call reflected the expectation that generics of Kisqali would enter the U.S. market in 2031.

It was better news for some of Novartis’ other key brands, with the company raising its peak sales guidance for Kesimpta from $6 billion to $8 billion, Scemblix from $4 billion to $5 billion, and Leqvio raised from $4 billion to $5 billion.

Elsewhere on the call, Narasimhan maintained his long-running stance that the Big Pharma is focused on deals in the “sub-$2 billion range.” 

“We don't assume any larger deals in the numbers that you see here,” he told journalists on the call. “Of course, if opportunities present themselves, we would look at them. But that's how we model our future.”

 

Watching China policy ‘very closely’

With anxiety growing across the industry about the potential impact of the U.S. Treasury’s proposals to include pharmaceuticals in the Comprehensive Outbound Investment National Security (COINS) Act, Fierce also asked Narasimhan on the call if the plans—which could in principle impact U.S. citizens such as the CEO—risked obstructing Novartis’ deal-making in China.

“We're watching very closely the whole development of this policy,” Narasimhan responded. “The ability of global companies and even companies with large U.S. footprints, like Novartis, to take [Chinese] technologies and allow workforces in the United States to work on those programs [and] produce those medicines is ultimately strategically advantaged for the United States.”

“And so think the scope of the rule needs to get adjusted in terms of the technology that's covered, as well as the types of deals that are covered as well. So we're advocating for that; the industry is advocating for that,” the CEO continued. 

“We're hopeful that the policy will ultimately adjust accordingly,” he added. “And then if it doesn't, structure ourselves accordingly to manage whatever the policy is. And so, because we're Swiss-based and we have a global management team, we're fully comfortable.”